Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 14
2003 10
2004 20
2005 18
2006 22
2007 22
2008 9
2009 9
2010 11
2011 13
2012 12
2013 13
2014 7
2015 10
2016 6
2017 10
2018 10
2019 10
2020 15
2021 6
2022 6
2023 7
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

245 results

Results by year

Filters applied: . Clear all
Page 1
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
Gien LT, Enserro DM, Block MS, Waggoner S, Duska LR, Wahner-Hendrickson AE, Thaker PH, Backes F, Kidd M, Muller CY, DiSilvestro PA, Covens A, Gershenson DM, Moore KN, Aghajanian C, Coleman RL. Gien LT, et al. Among authors: gershenson dm. Gynecol Oncol. 2024 Apr 10;186:61-68. doi: 10.1016/j.ygyno.2024.03.027. Online ahead of print. Gynecol Oncol. 2024. PMID: 38603953
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
Hollis RL, Elliott R, Dawson JC, Ilenkovan N, Matthews RM, Stillie LJ, Oswald AJ, Kim H, Llaurado Fernandez M, Churchman M, Porter JM, Roxburgh P, Unciti-Broceta A, Gershenson DM, Herrington CS, Carey MS, Carragher NO, Gourley C. Hollis RL, et al. Among authors: gershenson dm. Gynecol Oncol. 2024 Apr 5;186:42-52. doi: 10.1016/j.ygyno.2024.03.029. Online ahead of print. Gynecol Oncol. 2024. PMID: 38582027 Free article.
Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors.
How JA, Legarreta AF, Handley KF, Fellman B, Foster KI, Glassman D, Vuttaradhi VK, Brodsky AL, Lawson B, Frumovitz M, Westin SN, Ramondetta LM, Gershenson DM, Sood AK, Hillman RT. How JA, et al. Among authors: gershenson dm. Am J Obstet Gynecol. 2024 Jan 6:S0002-9378(24)00009-7. doi: 10.1016/j.ajog.2024.01.002. Online ahead of print. Am J Obstet Gynecol. 2024. PMID: 38191019
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.
Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Hinchcliff EM, et al. Among authors: gershenson dm. Cancer. 2024 Apr 1;130(7):1061-1071. doi: 10.1002/cncr.35126. Epub 2023 Nov 27. Cancer. 2024. PMID: 38009662 Clinical Trial.
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
Grisham RN, Slomovitz BM, Andrews N, Banerjee S, Brown J, Carey MS, Chui H, Coleman RL, Fader AN, Gaillard S, Gourley C, Sood AK, Monk BJ, Moore KN, Ray-Coquard I, Shih IM, Westin SN, Wong KK, Gershenson DM. Grisham RN, et al. Among authors: gershenson dm. Int J Gynecol Cancer. 2023 Sep 4;33(9):1331-1344. doi: 10.1136/ijgc-2023-004610. Int J Gynecol Cancer. 2023. PMID: 37591609 Free PMC article.
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Praiss AM, Miller A, Smith J, Lichtman SM, Bookman M, Aghajanian C, Sabbatini P, Backes F, Cohn DE, Argenta P, Friedlander M, Goodheart MJ, Mutch DG, Gershenson DM, Tewari KS, Wenham RM, Wahner Hendrickson AE, Lee RB, Gray H, Secord AA, Van Le L, O'Cearbhaill RE. Praiss AM, et al. Among authors: gershenson dm. Gynecol Oncol. 2023 Jul;174:213-223. doi: 10.1016/j.ygyno.2023.05.013. Epub 2023 May 23. Gynecol Oncol. 2023. PMID: 37229879 Clinical Trial.
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
Sia TY, Tew WP, Purdy C, Chi DS, Menzin AW, Lovecchio JL, Bookman MA, Cohn DE, Teoh DG, Friedlander M, Bender D, Mutch DG, Gershenson DM, Tewari KS, Wenham RM, Wahner Hendrickson AE, Lee RB, Gray HJ, Secord AA, Van Le L, Lichtman SM. Sia TY, et al. Among authors: gershenson dm. Gynecol Oncol. 2023 Jun;173:130-137. doi: 10.1016/j.ygyno.2023.03.018. Epub 2023 May 4. Gynecol Oncol. 2023. PMID: 37148580
Comparative Tumor Microenvironment Analysis of Primary and Recurrent Ovarian Granulosa Cell Tumors.
Khlebus E, Vuttaradhi VK, Welte T, Khurana N, Celestino J, Beird HC, Gumbs C, Little L, Legarreta AF, Fellman BM, Nguyen T, Lawson B, Ferri-Borgogno S, Mok SC, Broaddus RR, Gershenson DM, Futreal PA, Hillman RT. Khlebus E, et al. Among authors: gershenson dm. Mol Cancer Res. 2023 May 1;21(5):483-494. doi: 10.1158/1541-7786.MCR-22-0623. Mol Cancer Res. 2023. PMID: 37068116 Free PMC article.
245 results